Cargando…
Colorectal Cancer Immunotherapy: Options and Strategies
Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530194/ https://www.ncbi.nlm.nih.gov/pubmed/33042104 http://dx.doi.org/10.3389/fimmu.2020.01624 |
_version_ | 1783589519596978176 |
---|---|
author | Johdi, Nor Adzimah Sukor, Nur Fazilah |
author_facet | Johdi, Nor Adzimah Sukor, Nur Fazilah |
author_sort | Johdi, Nor Adzimah |
collection | PubMed |
description | Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients’ own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients’ own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life. |
format | Online Article Text |
id | pubmed-7530194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75301942020-10-09 Colorectal Cancer Immunotherapy: Options and Strategies Johdi, Nor Adzimah Sukor, Nur Fazilah Front Immunol Immunology Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients’ own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients’ own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life. Frontiers Media S.A. 2020-09-18 /pmc/articles/PMC7530194/ /pubmed/33042104 http://dx.doi.org/10.3389/fimmu.2020.01624 Text en Copyright © 2020 Johdi and Sukor. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Johdi, Nor Adzimah Sukor, Nur Fazilah Colorectal Cancer Immunotherapy: Options and Strategies |
title | Colorectal Cancer Immunotherapy: Options and Strategies |
title_full | Colorectal Cancer Immunotherapy: Options and Strategies |
title_fullStr | Colorectal Cancer Immunotherapy: Options and Strategies |
title_full_unstemmed | Colorectal Cancer Immunotherapy: Options and Strategies |
title_short | Colorectal Cancer Immunotherapy: Options and Strategies |
title_sort | colorectal cancer immunotherapy: options and strategies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530194/ https://www.ncbi.nlm.nih.gov/pubmed/33042104 http://dx.doi.org/10.3389/fimmu.2020.01624 |
work_keys_str_mv | AT johdinoradzimah colorectalcancerimmunotherapyoptionsandstrategies AT sukornurfazilah colorectalcancerimmunotherapyoptionsandstrategies |